Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy

OBJECTIVE: A minority of HIV-1 positive individuals treated with antiretroviral therapy (ART) in primary HIV-1 infection (PHI) maintain viral suppression on stopping. Whether this is related to ART duration has not been explored. DESIGN: And Methods: Using SPARTAC trial data from individuals recruit...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Stöhr, W, Fidler, S, McClure, M, Weber, J, Cooper, D, Ramjee, G, Kaleebu, P, Tambussi, G, Schechter, M, Babiker, A, Phillips, R, Porter, K, Frater, J
Formáid: Journal article
Teanga:English
Foilsithe / Cruthaithe: Public Library of Science 2013
_version_ 1826289148052373504
author Stöhr, W
Fidler, S
McClure, M
Weber, J
Cooper, D
Ramjee, G
Kaleebu, P
Tambussi, G
Schechter, M
Babiker, A
Phillips, R
Porter, K
Frater, J
author_facet Stöhr, W
Fidler, S
McClure, M
Weber, J
Cooper, D
Ramjee, G
Kaleebu, P
Tambussi, G
Schechter, M
Babiker, A
Phillips, R
Porter, K
Frater, J
author_sort Stöhr, W
collection OXFORD
description OBJECTIVE: A minority of HIV-1 positive individuals treated with antiretroviral therapy (ART) in primary HIV-1 infection (PHI) maintain viral suppression on stopping. Whether this is related to ART duration has not been explored. DESIGN: And Methods: Using SPARTAC trial data from individuals recruited within 6 months of seroconversion, we present an observational analysis investigating whether duration of ART was associated with post-treatment viraemic control. Kaplan-Meier estimates, logistic regression and Cox models were used. RESULTS: 165 participants reached plasma viral loads (VL) <400 copies/ml at the time of stopping therapy (ART stop). After ART stop, 159 experienced confirmed VL ≥400 copies/ml during median (IQR) follow-up of 167 (108,199) weeks. Most participants experienced VL rebound within 12 weeks from ART stop, however, there was a suggestion of a higher probability of remaining <400 copies/ml for those on ART >12 weeks compared to ≤12 weeks (p=0.061). Cumulative probabilities of remaining <400 copies/ml at 12, 52 and 104 weeks after ART stop were 21% (95%CI=13,30), 4% (1,9), and 4% (1,9) for ≤12 weeks ART, and 32% (22,42), 14% (7,22), and 5% (2,11) for >12 weeks. In multivariable regression, ART for >12 weeks was independently associated with a lower probability of being ≥400 copies/ml within 12 weeks of ART stop (OR=0.11 (95%CI=0.03,0.34), p<0.001)). In Cox models of time to VL ≥400 after 12 weeks, we only found an association with female sex (OR=0.2, p=0.001). CONCLUSION: Longer ART duration in PHI was associated with a higher probability of viral control after ART stop. TRIAL REGISTRATION: Controlled-Trials.com 76742797 http://www.controlled-trials.com/ISRCTN76742797.
first_indexed 2024-03-07T02:24:29Z
format Journal article
id oxford-uuid:a51e50f8-00fa-4be0-b2fd-9631c43a0b67
institution University of Oxford
language English
last_indexed 2024-03-07T02:24:29Z
publishDate 2013
publisher Public Library of Science
record_format dspace
spelling oxford-uuid:a51e50f8-00fa-4be0-b2fd-9631c43a0b672022-03-27T02:38:15ZDuration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a51e50f8-00fa-4be0-b2fd-9631c43a0b67EnglishSymplectic Elements at OxfordPublic Library of Science2013Stöhr, WFidler, SMcClure, MWeber, JCooper, DRamjee, GKaleebu, PTambussi, GSchechter, MBabiker, APhillips, RPorter, KFrater, JOBJECTIVE: A minority of HIV-1 positive individuals treated with antiretroviral therapy (ART) in primary HIV-1 infection (PHI) maintain viral suppression on stopping. Whether this is related to ART duration has not been explored. DESIGN: And Methods: Using SPARTAC trial data from individuals recruited within 6 months of seroconversion, we present an observational analysis investigating whether duration of ART was associated with post-treatment viraemic control. Kaplan-Meier estimates, logistic regression and Cox models were used. RESULTS: 165 participants reached plasma viral loads (VL) <400 copies/ml at the time of stopping therapy (ART stop). After ART stop, 159 experienced confirmed VL ≥400 copies/ml during median (IQR) follow-up of 167 (108,199) weeks. Most participants experienced VL rebound within 12 weeks from ART stop, however, there was a suggestion of a higher probability of remaining <400 copies/ml for those on ART >12 weeks compared to ≤12 weeks (p=0.061). Cumulative probabilities of remaining <400 copies/ml at 12, 52 and 104 weeks after ART stop were 21% (95%CI=13,30), 4% (1,9), and 4% (1,9) for ≤12 weeks ART, and 32% (22,42), 14% (7,22), and 5% (2,11) for >12 weeks. In multivariable regression, ART for >12 weeks was independently associated with a lower probability of being ≥400 copies/ml within 12 weeks of ART stop (OR=0.11 (95%CI=0.03,0.34), p<0.001)). In Cox models of time to VL ≥400 after 12 weeks, we only found an association with female sex (OR=0.2, p=0.001). CONCLUSION: Longer ART duration in PHI was associated with a higher probability of viral control after ART stop. TRIAL REGISTRATION: Controlled-Trials.com 76742797 http://www.controlled-trials.com/ISRCTN76742797.
spellingShingle Stöhr, W
Fidler, S
McClure, M
Weber, J
Cooper, D
Ramjee, G
Kaleebu, P
Tambussi, G
Schechter, M
Babiker, A
Phillips, R
Porter, K
Frater, J
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
title Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
title_full Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
title_fullStr Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
title_full_unstemmed Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
title_short Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
title_sort duration of hiv 1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
work_keys_str_mv AT stohrw durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT fidlers durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT mcclurem durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT weberj durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT cooperd durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT ramjeeg durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT kaleebup durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT tambussig durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT schechterm durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT babikera durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT phillipsr durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT porterk durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy
AT fraterj durationofhiv1viralsuppressiononcessationofantiretroviraltherapyinprimaryinfectioncorrelateswithtimeontherapy